Individual differences in prothrombin time-international normalized ratio variation following coadministration of the anticancer agents S-1 and warfarin: 3 Case reports

International Journal of Clinical Pharmacology and Therapeutics

Volumn 49, Issue 11, 2011, Pages 700-704

  Yamamuro, F ^a   Miki, A ^a   Kondo, G ^a   Maeda, T ^a   Satoh, H ^a   Hori, S ^a   Sawada, Y ^a  

^a UNIVERSITY OF TOKYO   (Japan)

Author keywords

Drug interaction; PT INR; S 1; Warfarin

Indexed keywords

ANTINEOPLASTIC AGENT; CA 19-9 ANTIGEN; CYTOCHROME P450 2A6; CYTOCHROME P450 2C9; DILTIAZEM; DRUG METABOLITE; ETIZOLAM; FAMOTIDINE; FLUOROURACIL; GIMERACIL PLUS OTERACIL POTASSIUM PLUS TEGAFUR; HEPARIN; INSULIN ASPART; ISOSORBIDE MONONITRATE; LANSOPRAZOLE; MAGNESIUM OXIDE; NICORANDIL; PACLITAXEL; REBAMIPIDE; RECOMBINANT HUMAN INSULIN; WARFARIN;

ADULT; AGED; ARTICLE; BLEEDING DISORDER; BRAIN EMBOLISM; BRAIN INFARCTION; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER STAGING; CASE REPORT; CLINICAL FEATURE; CORONARY ARTERY DISEASE; DIABETES MELLITUS; DOSE RESPONSE; DRUG ANTAGONISM; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG EFFECT; DRUG EFFICACY; DRUG INDICATION; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; GENETIC POLYMORPHISM; HUMAN; INTERNATIONAL NORMALIZED RATIO; KIDNEY FUNCTION; LUNG ADENOCARCINOMA; LUNG EMBOLISM; LYMPH NODE METASTASIS; MALE; MULTIPLE CYCLE TREATMENT; PROTHROMBIN TIME; SIDE EFFECT; STOMACH CANCER; TREATMENT DURATION;

AGED; ANTICOAGULANTS; ANTIMETABOLITES, ANTINEOPLASTIC; DRUG COMBINATIONS; DRUG INTERACTIONS; FEMALE; HUMANS; INTERNATIONAL NORMALIZED RATIO; MALE; MIDDLE AGED; OXONIC ACID; PROTHROMBIN TIME; TEGAFUR; WARFARIN;

EID: 80054788133     PISSN: 09461965     EISSN: None     Source Type: Journal    
DOI: 10.5414/CP201494     Document Type: Article

References (22)

1. Saif MW. An adverse interaction between warfarin and fluoropyrimidines revisited. Clin Colorectal Cancer. 2005; 5: 175-180. doi:10.3816/CCC.2005.n.028 PubMed
2. Shirasaka T. Development history and concept of an oral anticancer agent S-1 (TS-1): its clinical usefulness and future vistas. Jpn J Clin Oncol. 2009; 39: 2-15. doi:10.1093/jjco/hyn127 PubMed
3. Ikeda M, Furukawa H, Imamura H, Shimizu J, Ishida H, Masutani S, Tatsuta M, Kawasaki T, Satomi T. Pharmacokinetic study of S-1, a novel oral fluorouracil antitumor agent in animal model and in patients with impaired renal function. Cancer Chemother Pharmacol. 2002; 50: 25-32. doi:10.1007/s00280-002-0457-z PubMed (Pubitemid 34743992)
4. Lindh JD, Holm L, Andersson ML, Rane A. Influence of CYP2C9 genotype on warfarin dose requirements - a systematic review and meta-analysis. Eur J Clin Pharmacol. 2009; 65: 365-375. doi:10.1007/s00228-008-0584-5 PubMed
5. International Warfarin Pharmacogenetics Consortium, Klein TE, Altman RB. Estimation of the warfarin dose with clinical and pharmacokinetic data. N Engl J Med. 2009; 8: 753-764. PubMed
6. Lee AY, Levine MN, Baker RI, Bowden C, Kakkar AK, Prins M, Rickles FR, Julian JA, Haley S, Kovacs MJ, Gent M; Randomized comparison of low-molecular-weight heparin versus oral anticoagulant therapy for the prevention of recurrent venous thromboembolism in patients with cancer (CLOT) investigators. Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. N Engl J Med. 2003; 349: 146-153. doi:10.1056/NEJMoa025313 PubMed
7. Akl EA, Barba M, Rohilla S, Terrenato I, Sperati F, Muti P, Schünemann HJ. Anticoagulation for the long term treatment of venous thromboembolism in patients with cancer. Cochrane Database Syst Rev. 2008; CD006650. PubMed
8. Romera-Villegas A, Cairols-Castellote MA, Vila-Coll R, Martí-Mestre X, Colomé E, Iguaz I. Long-term use of different doses of low-molecular-weight heparin versus vitamin K antagonists in the treatment of venous thromboembolism. Ann Vasc Surg. 2010; 24: 628-639. doi:10.1016/j.avsg.2009.08.006 PubMed
9. Horn JR, Hansten PD, Chan LN. Proposal for a new tool to evaluate drug interaction cases. Ann Pharmacother. 2007; 41: 674-680. doi:10.1345/aph.1H423 PubMed (Pubitemid 46625492)
10. Prandoni P. How I treat venous thromboembolism in patients with cancer. Blood. 2005; 106: 4027-4033. doi:10.1182/blood-2005-04-1508 PubMed (Pubitemid 41775905)
11. Igarashi H, Maeda Y, Kasamatsu Y. Drug lnteraction between S-1 and Warfarin. J Jpn Soc Hosp Pharm. 2009; 45: 1321-1324. Article in Japanese
12. Marutaka M, Kubota Y, Yoshida R, Orita Y. Difficult management of warfarin anticoagulant therapy due to S-1 administration for gastric cancer - report of a case. Gan To Kagaku Ryoho. 2009; 36: 1561-1563. Article in Japanese PubMed
13. Yasui Y, Nishiguchi T, Yamamoto A, Fujii C, Fujino M, Tsuge M, Ohno M, Azuma J, Matsumura T, Ohsato H, Anami S, Furukawa H. A case of bleeding tendency due to warfarin in a patient treated with chemotherapy by S-1. Gan To Kagaku Ryoho. 2008; 35: 1367-1370. Article in Japanese PubMed
14. Fukami K, Seki K, Kitamura M. Case of Drug Interaction between 5-Fluorouracil and other Drugs. J Jpn Soc Hosp Pharm. 2008; 44: 286-288. Article in Japanese
15. Yoshisue K, Nagayama S, Shindo T, Kawaguchi Y. Effects of 5-fluorouracil on the drug-metabolizing enzymes of the small intestine and the consequent drug interaction with nifedipine in rats. J Pharmacol Exp Ther. 2001; 297: 1166-1175. PubMed (Pubitemid 32472518)
16. Stupans I, Richards DA, McClure MT. Effects of 5-fluorouracil treatment on rat liver microsomal enzymes. Xenobiotica. 1995; 25: 1-8. doi:10.3109/00498259509061827 PubMed
17. Camidge R, Reigner B, Cassidy J, Grange S, Abt M, Weidekamm E, Jodrell D. Significant effect of capecitabine on the pharmacokinetics and pharmacodynamics of warfarin in patients with cancer. J Clin Oncol. 2005; 23: 4719-4725. doi:10.1200/JCO.2005.09.129 PubMed (Pubitemid 46224075)
18. Brown MC. Multisite mucous membrane bleeding due to a possible interaction between warfarin and 5-fluorouracil. Pharmacotherapy. 1997; 17: 631-633. PubMed (Pubitemid 27227573)
19. Product information of Teysuno. http://www.ema.europa.eu/docs/en-GB/ document-library/EPAR-Product-Information/human/001242/WC500104415.pdf, p.19.
20. Park JY, Kim KA. Inhibitory effect of 5-fluorouracil on human cytochrome P(450) isoforms in human liver microsomes. Eur J Clin Pharmacol. 2003; 59: 407-409. doi:10.1007/s00228-003-0641-z PubMed
21. Afsar A, Lee C, Riddick DS. Modulation of the expression on constitutive rat hepatic cytochrome P450 isozymes by 5-fluorouracil. Can J Physiol Pharmacol. 1996; 74: 150-156. PubMed (Pubitemid 26153457)
22. Gunes A, Coskun U, Boruban C, Gunel N, Babaoglu MO, Sencan O, Bozkurt A, Rane A, Hassan M, Zengil H, Yasar U. Inhibitory effect of 5-fluorouracil on cytochrome P450 2C9 activity in cancer patients. Basic Clin Pharmacol Toxicol. 2006; 98: 197-200. doi:10.1111/j.1742-7843.2006.pto-304.x PubMed